Prelude Therapeutics Incorporated

NasdaqGS:PRLD 주식 보고서

시가총액: US$116.7m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Prelude Therapeutics 미래 성장

Future 기준 확인 0/6

Prelude Therapeutics 의 수익은 연간 8.3% 감소할 것으로 예상되는 반면, 연간 수익은 88.5% 로 증가할 것으로 예상됩니다. 88.5% 연간. EPS는 연간 7.6% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -125.3% 로 예상됩니다.

주요 정보

-8.2%

수익 성장률

7.6%

EPS 성장률

Biotechs 수익 성장28.5%
매출 성장률89.0%
향후 자기자본 수익률-125.3%
애널리스트 커버리지

Low

마지막 업데이트19 Sep 2024

최근 미래 성장 업데이트

Recent updates

We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate

Sep 16
We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate

We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully

May 09
We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully

Prelude Therapeutics: Scientifically Interesting Oncology Company With Preclinical Data

Feb 03

Here's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation

Sep 17
Here's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation

We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully

May 28
We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully

Here's Why We're Not Too Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation

Jan 28
Here's Why We're Not Too Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation

We're Hopeful That Prelude Therapeutics (NASDAQ:PRLD) Will Use Its Cash Wisely

Oct 27
We're Hopeful That Prelude Therapeutics (NASDAQ:PRLD) Will Use Its Cash Wisely

Prelude wins FDA clearance to start Phase 1 trial for cancer candidate

Oct 18

Prelude downgraded at Morgan Stanley ahead of key update

Sep 09

We're Not Very Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate

Jun 28
We're Not Very Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate

Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth

Mar 14
Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth

We Think Prelude Therapeutics (NASDAQ:PRLD) Can Afford To Drive Business Growth

Dec 14
We Think Prelude Therapeutics (NASDAQ:PRLD) Can Afford To Drive Business Growth

Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth

Jul 05
Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth

What Type Of Shareholders Own The Most Number of Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares?

Feb 16
What Type Of Shareholders Own The Most Number of Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares?

Prelude Therapeutics prices $150M share offering

Jan 07

Prelude Therapeutics readies public offering

Jan 04

Read This Before Selling Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares

Dec 25
Read This Before Selling Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares

수익 및 매출 성장 예측

NasdaqGS:PRLD - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/2026N/A-162-136N/A2
12/31/2025N/A-152-132N/A3
12/31/2024N/A-139-125N/A3
6/30/2024N/A-130-106-104N/A
3/31/2024N/A-126-112-109N/A
12/31/2023N/A-122-111-107N/A
9/30/2023N/A-117-109-106N/A
6/30/2023N/A-117-104-101N/A
3/31/2023N/A-114-95-92N/A
12/31/2022N/A-115-87-84N/A
9/30/2022N/A-120-89-87N/A
6/30/2022N/A-120-91-88N/A
3/31/2022N/A-120-92-89N/A
12/31/2021N/A-112-86-84N/A
9/30/2021N/A-98-75-73N/A
6/30/2021N/A-84-65-63N/A
3/31/2021N/A-69-54-52N/A
12/31/2020N/A-57-47-46N/A
9/30/2020N/A-48-40-40N/A
6/30/2020N/A-38-34-33N/A
3/31/2020N/A-32-31-30N/A
12/31/2019N/A-28-26-26N/A

애널리스트 미래 성장 예측

수입 대 저축률: PRLD 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: PRLD 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: PRLD 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: PRLD 은(는) 내년에 수익이 없을 것으로 예상됩니다.

고성장 수익: PRLD 은(는) 내년에 수익이 없을 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: PRLD (는) 3년 내에 수익성이 없을 것으로 예상됩니다.


성장 기업 발견